Preformulation Studies on Piperlongumine

被引:25
|
作者
Aodah, Alhassan [1 ]
Pavlik, Aaron [1 ]
Karlage, Kelly [1 ]
Myrdal, Paul B. [1 ]
机构
[1] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA
来源
PLOS ONE | 2016年 / 11卷 / 03期
关键词
CANCER-CELLS; ANOIKIS RESISTANCE; STAT3;
D O I
10.1371/journal.pone.0151707
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Piperlongumine is a natural alkaloid extracted from piper plants which has been used traditionally for the treatment of certain diseases. This compound shows interesting in vitro pharmacological activity such as selective anticancer activity and higher cytotoxicity than methotrexate, cyclophosphamide and adriamycin on breast, colon, and osteosarcoma cancers, respectively. However, the physicochemical properties for this compound have not been well characterized. In this research, preformulation studies for piperlongumine have been performed to determine factors which influence solubility and stability which, in turn, can be used to assist future formulation development. The solubility of piperlongumine in water was found to be approximately 26 mu g/ml. Using 10% polysorbate 80 as a surfactant resulted in a 27 fold increase in solubility. Cosolvents and cyclodextrins afforded concentrations of 1 mg/ml and higher. The pH degradation rate profile for piperlongumine at various temperatures shows significant instability of the drug at pH values >= 7 and 3, and maximum stability around pH 4. It was estimated that it would take approximately 17 weeks for piperlongumine to degrade by 10% at 25 degrees C, pH 4. Additionally, piperlongumine showed marked photo-degradation upon exposure to an ultraviolet light source, especially in aqueous media.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Preformulation studies of levonorgestrel
    Ridichie, Amalia
    Ledeti, Adriana
    Sbarcea, Laura
    Rusu, Gerlinde
    Muntean, Cornelia
    Circioban, Denisa
    Peter, Francisc
    Ledeti, Ionut
    [J]. JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY, 2024,
  • [2] Preformulation studies on Imexon
    Kuehl, PJ
    Hoye, WL
    Myrdal, PB
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (06) : 687 - 697
  • [3] AN OVERVIEW ON PREFORMULATION STUDIES
    Desu, Prasanna Kumar
    Vaishnavi, G.
    Divya, K.
    Lakshmi, U.
    [J]. INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2015, 2 (10): : 1399 - 1407
  • [4] Polymorphism and preformulation studies of lifibrol
    Burger, A
    Lettenbichler, A
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 49 (01) : 65 - 72
  • [5] Expediting Early Preformulation Studies
    Middaugh, C. Russell
    [J]. GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2012, 32 (15): : 42 - 43
  • [6] PREFORMULATION STUDIES FOR A PARENTERAL SOLUTION OF MEMANTINE
    Achim, Marcela
    Vlase, Laurian
    Tomuta, Ioan
    Muntean, Dana
    Iuga, Cristina
    Georgescu, Radu
    Leucuta, Sorin
    [J]. FARMACIA, 2011, 59 (05) : 636 - 646
  • [7] Transdermal delivery of phenobarbital Preformulation studies
    Odri, S.
    Stupar, M.
    Eros, I.
    Antal, I.
    Klebovich, I.
    Szabo-Revesz, P.
    Csanyi, E.
    [J]. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2008, 18 (06) : 417 - 423
  • [8] PREFORMULATION STUDIES ON NAPROXEN SODIUM SUPPOSITORIES
    SANTUS, G
    GIORDANO, F
    GAZZANIGA, A
    BRUNI, G
    PAIOTTI, S
    YAN, JX
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1994, 40 (04) : 243 - 245
  • [9] Preformulation Studies on Palonosetron Hydrochloride Injection
    Ramya, S.
    Bose, P. S. C.
    Nagaraju, R.
    [J]. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 71 (02) : 165 - 165
  • [10] Preformulation Studies Of S-Equol
    Bhongiri, Bhargav
    Ramachandran, Vadivelan
    Kumar, Raman Suresh
    [J]. JOURNAL OF PHARMACEUTICAL NEGATIVE RESULTS, 2022, 13 : 1020 - 1029